Belite Bio (BLTE) vs Kiniksa Pharmaceuticals International (KNSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Kiniksa Pharmaceuticals International (KNSA) has outperformed Belite Bio (BLTE) over the past year, gaining 104.5% versus a gain of 101.7%. Belite Bio is the larger company by market cap ($6.29 billion vs $6.08 billion), about 1.0 times the size. On valuation, Kiniksa Pharmaceuticals International trades at a lower forward P/E (48.2x vs 69.1x for Belite Bio).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLTE | KNSA |
|---|---|---|
| Share price | $156.08 | $77.96 |
| Market cap | $6.29B | $6.08B |
| 1-day change | +0.30% | +1.13% |
| YTD return | -2.43% | +88.99% |
| 1-year return | +101.65% | +104.51% |
| 5-year return | — | +580.87% |
| P/E ratio (TTM) | — | 78.75 |
| Forward P/E | 69.06 | 48.20 |
| EPS (TTM) | $-2.74 | $0.99 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $677.56M |
| Revenue growth (YoY) | — | +60.09% |
| Net income (latest FY) | $-77.61M | $59.01M |
| Gross margin | — | 88.54% |
| Operating margin | — | 11.40% |
| Net margin | — | 8.71% |
| 52-week high | $200.00 | $82.94 |
| 52-week low | $76.50 | $35.20 |
| Distance from 52-week high | -21.96% | -6.00% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +46.65% | +25.71% |
| Average volume | 182.25K | 589.58K |
| Shares outstanding | 40.27M | 48.29M |
| Employees | 41 | 366 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Belite Bio
BLTE stock →Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 41 employees
About Kiniksa Pharmaceuticals International
KNSA stock →Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 366 employees
BLTE vs KNSA FAQ
Which is bigger, Belite Bio or Kiniksa Pharmaceuticals International?
Belite Bio (BLTE) is larger, with a market capitalization of $6.29B compared with $6.08B for Kiniksa Pharmaceuticals International (KNSA).
Which stock has performed better over the past year, BLTE or KNSA?
KNSA returned +104.51% over the past 12 months, compared with +101.65% for BLTE (price return, excluding dividends). Past performance does not predict future results.
Are Belite Bio and Kiniksa Pharmaceuticals International in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.